In addition, we observed that a high level of OCT4 expression is required for the initial reprogramming and the optimal iMSC self-renewal, while a reduction of OCT4 expression is required for multilineage differentiation. Our method will contribute to the generation of patient-specific iMSCs, which could have applications in regenerative medicine. This discovery may also facilitate the development of strategies for direct conversion of blood cells into other types of cells of clinical importance.
Introduction
Mesenchymal stem cells (MSCs) are somatic stem cells responsible for the regeneration of cartilage, tendon, ligament, muscle and bone, and thus hold great promise for treating skeletal diseases [1] [2] [3] [4] [5] . Due to their immunomodulatory potential, MSCs have also been used in clinical and preclinical studies to treat multiple diseases including graft versus host disease (GVHD) [6] , Crohn's disease [7] , organ transplant rejection [8] and diabetes [9] . MSCs can be isolated from multiple tissues like bone marrow (BM) and adipose tissue [10] . However, the procedures are invasive and often yield limited numbers of MSCs for therapy. MSCs differentiated from human induced pluripotent stem cells (iPSCs) have been used for skeletal regeneration and tissue repair [11] [12] [13] . However, this approach is time-consuming, and the risk www.cell-research.com | Cell Research Xianmei Meng et al. 659
npg of teratoma formation due to trace amount of undifferentiated or contaminated iPSCs in iPSC-MSCs remains a concern. Thus, the direct reprogramming of somatic cells into MSCs presents an alternative to the iPSC approach and might decrease the risk of teratoma formation. The direct reprogramming of one type of cells, most commonly fibroblasts, into another by ectopic expression of defined transcription factors has recently been achieved. Successful reprogramming of human or mouse fibroblasts into neural stem cells [14] [15] , cardiomyocytes [16] [17] and hepatocytes [18] [19] has been reported. The most readily available cell sources of adult human are skin and blood. The use of blood cells for reprogramming has unique advantages over dermal fibroblasts, as blood cells likely harbor fewer acquired genetic mutations induced by environmental insults, and can be easily obtained from patients with minimal invasiveness [20] [21] [22] [23] . The first report of direct reprogramming of blood cells into somatic cells of clinical interest, such as neuronal cells, has recently been published [24] . Cord blood (CB)-CD133 + progenitor cells are reprogrammed to neuronal cells by ectopic expression of SOX2 and MYC at an efficiency of < 0.1%, requiring 3 weeks for the generation of neuronal cell-like colonies [24] . In addition, the use of the oncogene MYC poses a serious risk of tumorigenesis. Thus, we have been interested in identifying an approach that can generate MSCs safely, rapidly and efficiently from blood cells. Here, we present a novel approach for generating self-renewable, multipotent and non-tumorigenic induced mesenchymal stem cells (iMSCs) from human blood CD34 + cells by direct reprogramming with only one factor.
Results

Generation of iMSCs from CB-CD34
+ cells We have previously reported the efficient generation of iPSCs from human CB-CD34 + cells with a single vector that expresses OCT4 and SOX2 (Lenti SFFV-OCT4-2A-SOX2) [25] . When the two factors were expressed by two individual lentiviral vectors (Lenti SFFV-OCT4 and Lenti SFFV-SOX2), we observed that ~80% of the colonies morphologically resemble mesenchymal cells. This finding prompted us to explore whether OCT4 or SOX2 alone can reprogram CD34 + cells directly into MSC-like cells, which we term as induced MSCs (iMSCs) hereafter for brevity. We found that transduction of CB-CD34 + cells with Lenti SFFV-OCT4, but not Lenti SFFV-SOX2, induced iMSC formation (Supplementary information, Figure S1A ), suggesting that OCT4 is responsible for the induced cell fate conversion. We also tested other reprogramming factors and found that MYC, NANOG, KLF4, LIN28 or TBX3 alone completely failed to convert CB-CD34 + cells into iMSCs (Supplementary information, Figure S1B ). Furthermore, the combination of these factors with OCT4 did not significantly increase the reprogramming efficiency. Thus, our subsequent studies focused on OCT4 only.
A successful iMSC conversion depends on OCT4 overexpression and MSC-conducive culture conditions. The transduction of CB-CD34
+ cells with green fluorescent protein (GFP) control did not generate MSCs ( Figure  1A and Supplementary information, Video S1), whereas OCT4-transduced cells formed colonies and were transformed morphologically into spindle-like cells within 3-4 days of culture in MSC-conducive conditions ( Figure  1B and Supplementary information, Video S2). Some OCT4-transduced cells cultured in hematopoietic stem cell (HSC) medium manifested a spindle-like morphology, but died shortly after the formation of small colonies ( Figure 1C and Supplementary information, Video S3). We also found that the use of human fibronectin-precoated non-tissue culture-treated (non-TC) culture plates that allow for efficient attachment of transduced CB-CD34 + cells is crucial for the rapid morphological transformation (1 week), whereas in the absence of fibronectin, the morphological transformation takes 2-3 weeks.
To optimize the reprogramming protocol, we tested whether small molecules capable of enhancing the reprogramming of somatic cells into iPSCs, such as GSK3 inhibitor CHIR99021 (CHIR), MEK inhibitor and ALK5 inhibitor, can also increase the efficiency of direct reprogramming of CB-CD34 + cells into iMSCs. After a series of experiments, we found that only CHIR can substantially enhance the reprogramming process; it increased the reprogramming efficiency from 3% to 16% ( Figure  1D and 1E). Colonies were also substantially larger in size in the presence of CHIR ( Figure 1D ). Moreover, CHIR consistently increased the iMSC proliferation rate in long-term cultures ( Figure 1F) , and shortened the population doubling time from 35 h to 20 h. These data demonstrate that CHIR increases both the reprogramming efficiency and the in vitro proliferative rate of iMSCs.
The transition of CB-CD34 + cells to phenotypically mature iMSCs takes several weeks. During the first 2 weeks of the transdifferentiation, cells expressing the pan-hematopoietic marker, CD45, steadily decreased from > 99% to < 1%, whereas cells expressing the MSC marker, CD73, rapidly increased from 0% to > 70% (Figure 1G and Supplementary information, Figure S2A ). MSC markers CD29 and CD44 were also expressed in HSCs, but at low levels. Of interest, we observed a 15-fold and 6-fold increase of the expression of CD29 and CD44, respectively, over 3-4 weeks (Supplementary Figure 1H ), whereas the expression of the hematopoietic markers CD45, CD34 and CD14, or the endothelial marker CD31 was negligible ( Figure 1I ). These data provide evidence that fully reprogrammed iMSCs are phenotypically identical to MSCs from other sources.
OCT4-reprogrammed iMSCs are genetically stable and do not form tumors
We further examined the in vitro long-term proliferative capacity and potential risk of tumor formation of iMSCs. In five independent experiments, the iMSCs expanded robustly over the 4 months of culture, with a cell population doubling time of 20-22 h in the presence of CHIR (Supplementary information, Figure S3 ). Of note, the rate of cellular proliferation was virtually unchanged during the entire period of culture, with no signs of senescence or transformation based on the frequency of cell division. We asked whether OCT4 expression induces genomic instability after long-term in vitro culture. Karyotype analysis did not detect any major chromosomal abnormalities ( Figure 1J ). To further investigate the safety of these cells, we injected 1-2 × 10 6 iMSCs systemically or subcutaneously into 20 immunodeficient mice. Unlike iPSCs [25] , iMSCs did not form tumors during 3 months of follow-up. In comparison, injection of iMSCs that were generated with OCT4 and MYC led to tumor formation at 1 month after systemic or subcutaneous inoculation (data not shown). These data suggest that the use of OCT4 for direct reprogramming of CB-CD34 + cells into iMSCs is a safe approach for rapid generation of large quantities of MSCs.
iMSCs are reprogrammed directly from hematopoietic progenitors, not from mature myeloid cells
As MSCs are present in the CB at frequencies ranging from 0 to 2.3 clones per 1 × 10 8 mononuclear cells or ~0.1 clones per ml [26] , we asked whether OCT4 expands the contaminated MSCs in CB-CD34 + cells rather than directly reprogramming hematopoietic cells into iMSCs. The proliferation of the existing MSCs in the CB cannot explain iMSC generation, as no MSCs were generated from nontransduced CB-CD34 + cells after 2-3 weeks of culture under our MSC culture conditions. To unambiguously test this possibility, we cloned single CB-CD34 + cells in U-bottomed 96-well plates. After 10 days of culture in medium supplemented with cytokines TPO, SCF, FL, IL-3 and G-CSF, hematopoietic cell colonies were formed in ~10% of the wells (Supplementary information, Figure S4 ). Random selection of 12 clones, followed by transduction with Lenti SFFV-OCT4 led to the formation of iMSCs in 33% cases (Supplementary information, Figure S4 ). These data demonstrate that iMSCs are directly reprogrammed from hematopoietic cells. Of interest, when CB-CD34 + cells were cultured in the condition that promotes myeloid differentiation for 20 days before OCT4-transduction, no iMSC colonies were generated from 12 randomly selected individual clones (data not shown). These data suggest that OCT4 likely reprograms hematopoietic progenitors into iMSCs, but cells in the terminal stages of myeloid differentiation cannot be reprogrammed by OCT4 overexpression.
Reprogramming to iMSCs requires a high level of OCT4 expression and lacks an iPSC stage
Next, we examined the potential mechanisms of OCT4-mediated direct reprogramming from CB-CD34 + cells into iMSCs. Consistent with our previous report [25] , we found that the iMSC reprogramming critically depends on OCT4 expression levels. When we used a relatively weak promoter such as EF1α or PGK that leads to 50%-60% lower expression of OCT4 compared to the SFFV promoter in hematopoietic cells [25] , the reprogramming from CB-CD34 + cells into iMSCs completely failed. This result suggests that a high level of OCT4 expression is necessary for the successful reprogramming of hematopoietic cells.
We then asked whether a pluripotent state is induced during the transdifferentiation process. Apart from OCT4, whose expression level is similar to that in iPSCs ( Figure 2A and Supplementary information, Figure S5 ), other pluripotency markers, such as SOX2, NANOG and TRA-1-60 were undetectable in iMSCs ( Figure 2A ). Bisulphite sequencing showed that OCT4 and NANOG promoters are hypermethylated ( Figure 2B ), suggesting that the endogenous OCT4 gene is not activated in iMSCs. We also found that OCT4 alone is insufficient for the reprogramming of CB-CD34 + cells into iPSCs and that the culture of iMSCs in iPSC-conducive conditions does not lead to the formation of iPSC colonies ( Figure  2C and 2D). Taken together, our data suggest that reprogramming of CB-CD34 + cells into iMSCs does not go through an iPSC stage.
A high level of OCT4 expression inhibits iMSC differentiation
MSCs have the capacity to differentiate into adipocytes, osteoblasts and chondrocytes in differentiationinducing conditions. However, iMSCs generated by transduction with the lentiviral vector SFFV-OCT4 (Lenti iMSCs) failed to differentiate into mature progenies of MSCs ( Figure 3A-3C ). A previous study shows that ectopic expression of OCT4 blocks the differentiation of epithelial progenitors [27] . We thus hypothesized that a high level of OCT4 expression promotes self-renewal, but inhibits differentiation of iMSCs. As predicted, after knockdown (KD) of OCT4 by 80% with an shOCT4 lentiviral vector (Supplementary information, Figure S5 ), iMSCs differentiated into mature adipocytes, osteoblasts Figure S6 ). We also observed that OCT4-KD leads to appreciable changes in morphology: Lenti iMSCsexpressing shOCT4 became more spindle-like compared with regular Lenti iMSCs ( Figure 3J and 3K). To further evaluate the roles of OCT4 in MSC differentiation, we transduced BM-MSCs with OCT4. As expected, OCT4 overexpression in BM-MSCs led to differentiation failure ( Figure 3L-3Q ). Taken together, these data demonstrate that a high level of OCT4 blocks MSC differentiation, and a reduction of OCT4 expression allows for multilineage differentiation.
Generation of integration-free iMSCs with an episomal vector
As a high level of constitutively expressed OCT4 inhibits iMSC differentiation and the use of integrating viral vector may limit the potential clinical applications, we attempted to reprogram CB-CD34 + cells into iMSCs by a transient OCT4 overexpression with a non-integrating episomal vector (EV) [25, 28] . After nucleofection of CB-CD34 + cells with EV SFFV-OCT4 plasmid DNA, we successfully generated iMSCs in 2 weeks, which we hereafter term as EV iMSCs for brevity. After 1 month of culture, OCT4 expression in EV iMSC decreased to baseline levels as observed in BM-MSCs (Supplementary information, Figure S5 ). EV iMSCs and BM-MSCs were morphologically identical ( Figure 4A and 4B). In addition, EV iMSCs did not differ from regular MSCs in the expression of typical MSC markers (Supplementary information, Figure S7 ).
We next tested the in vitro differentiation potential of EV iMSCs in comparison with BM-MSCs. EV iMSCs fully differentiated into adipocytes, osteoblasts and chondrocytes, with the similar differentiation potentials as BM-MSCs ( Figures 3L-3N , 4C-4E and Supplementary information, Figure S8 ). Further, results from RT-qPCR analyses showed similar expression levels for a majority of lineage-associated genes in adipocytes, osteoblasts and chondrocytes differentiated from EV iMSCs as compared to those differentiated from BM-MSCs ( Figure  4F-4H ). Of interest, the expression of SOX9, ACAN and COL2A1 appeared to be higher in chondrocyte cultures of EV iMSCs than those of BM-MSCs. These data suggest that EV iMSCs are similar to BM-MSCs in the in vitro multilineage differentiation potency.
In vivo functionality of iMSCs
To evaluate the potential for clinical application of iMSCs, we further investigated the in vivo functionality of EV iMSCs. Cells were transduced with GFP to facilitate the analyses of human cells in mice. HA-TCP bone graft substitute blocks loaded with iMSCs were subcutaneously implanted in nude mice. Analyses of the implants 2-3 months later showed that iMSCs differentiated into bone tissue, connective fibers and adipose tissue in all 10 animals, and into skeletal muscle fibers in the majority of the implants (Figure 5A-5D ). Immunohistological staining of GFP confirmed that the differentiated tissues were derived from human EV iMSCs ( Figure 5E ). Of interest, the implanted BM-MSCs differentiated into bone tissue, connective fibers and adipose tissue but not skeletal muscle fibers (Supplementary information, Figure S9 ). These data suggest that iMSCs may hold a functional advantage in promoting muscle regeneration.
Long-term proliferation and self-renewal of multipotent iMSCs depend on a low level of ectopic OCT4 expression
Primary adult human BM-MSCs display slowed proliferation after ~1 month in culture, and eventually stop growing and lose multilineage differentiation potential. We thus tested the in vitro proliferative potential of EV iMSCs. EV iMSCs showed an enhanced in vitro proliferative capacity compared with BM-MSCs -more than 100-fold more MSCs can be generated from the CB by transient OCT4 transfection than from the same volume of BM at 6 weeks after initiation of in vitro culture ( Figure  6A ). After ~15 passages in culture, EV iMSCs discontinued cell division and manifested the typical morphology of aged MSCs ( Figure 6B) .
Together with the observation of an unrestricted proliferative potential of Lenti iMSCs, we hypothesized that a low level of OCT4 expression may allow for long-term iMSC proliferation without blocking differentiation. To test this hypothesis, we selected a very weak promoter, the Sca1 promoter, which drives OCT4 expression at ~5% of the level in Lenti iMSCs or iPSCs (Supplementary information, Figure S5 ). After transducing EV iMSCs with Lenti Sca1-OCT4, these cells can be cultured for more than 30 passages, with a doubling time of ~40 h. In addition, Sca1-OCT4 iMSCs at passage 30 were still morphologically indistinguishable from BM-MSCs at earlier passages ( Figure 6C ). In addition, Sca1-OCT4 iMSCs readily differentiate into adipocytes, osteoblasts and chondrocytes in induction cultures (data not shown), suggesting that maintaining a low level of OCT4 expression in iMSCs allows for long-term proliferation, yet does not affect the in vitro multilineage differentiation potential of these cells.
Generation of iMSCs from adult human peripheral blood CD34
+ cells Our findings with fetal blood prompted us to test whether OCT4 can also reprogram adult human peripheral blood (PB) cells into iMSCs. After transduction of PB-CD34 + cells with Lenti SFFV-OCT4, iMSC colonies were formed within 1 week. The reprogramming of PBand CB-CD34 + cells was equally efficient. CHIR also increased the reprogramming efficiency of PB-CD34 + cells from 3% to 15% (Figure 7A and 7B) . In addition, PB-Lenti iMSCs were morphologically and phenotypically identical to CB-Lenti iMSCs ( Figure 7C vs Figure  3J , and data not shown). These data suggest that OCT4 can reprogram both fetal and adult human hematopoietic 
Discussion
Here, we report that a single transcription factor, OCT4, allows for rapid and efficient reprogramming of human CD34 + cells from either CB or adult PB directly into iMSCs. The ability to reprogram blood cells into self-renewable iMSCs at an unprecedented efficiency has important implications for regenerative medicine. Although MSCs have been isolated from many sources [10] , our approach for generating iMSCs from the pa- tient's own blood cells should find its applications in the treatment of diseases such as arthritis and muscular dystrophy. The iMSCs are multipotent, being able to differentiate into different types of MSC progenies both in vitro and in vivo, and are not tumorigenic. In addition, with the use of an episomal vector, integration-free iMSCs can be generated. We also demonstrate a dosage effect of OCT4: a high level of OCT4 is required for efficient reprogramming, but blocks in vitro multilineage differentiation, whereas a low level of OCT4 promotes long-term self-renewal and proliferation but does not affect differentiation of iMSCs.
Due to the limited proliferative potential of MSCs derived from adult bone marrow or adipose tissue, many Figure 5 In vivo multilineage differentiation capacity of iMSCs. Two to three months after subcutaneous implantation of 1 × 10 6 EV iMSCs in HA-TCP blocks to nude mice, the implants were harvested for microsectioning and H&E staining analyses. (A) Newly formed bone matrix derived from the implanted iMSCs (400×). Bone matrix was formed in all of the implants (n = 10). [11, [29] [30] [31] . The iMSC approach sidesteps the need for iPSC generation, and thus shortens the time required for generating large quantities of patient-specific MSCs from several months to several weeks, and lowers or even abrogates the risk of teratoma formation. We also demonstrate that iMSCs can differentiate to generate skeletal muscle, pointing to their potential applications in treating muscular disorders. OCT4 is a master transcription factor that helps to maintain the pluripotency of embryonic stem cells and plays a pivotal role in the generation of iPSCs [32] [33] [34] . However, whether OCT4 is expressed in somatic stem cells like MSCs is controversial. Many earlier reports of OCT4 expression in somatic stem cells are likely due to artifacts caused by background noises and the expression of OCT4 pseudogenes [35] [36] . In addition, conditional knockout studies in mice demonstrate that OCT4 is functionally dispensable in self-renewal and differentiation of adult BM-MSCs [37] . However, the observation that OCT4 is not required for in vivo self-renewal of MSCs does not necessarily argue against the expression of OCT4 in MSCs during ex vivo culture and its potential effects on the functionality of MSCs. Recent reports have provided evidence that OCT4 expression is higher in MSCs at early passages compared with MSCs at late passages [38] [39] . They also found that OCT4-KD in MSCs decreases the proliferation potential and enhances spontaneous differentiation of MSCs, whereas OCT4 overexpression in MSCs increases proliferation and sup- presses spontaneous differentiation [39] . These data suggest an important role of OCT4 in maintaining the selfrenewal of MSCs. This conclusion is further supported by a transgenic mouse study showing that ectopic OCT4 expression blocks the differentiation of epithelial progenitors [27] . Consistent with these observations, we show that a high level of ectopic OCT4 expression promotes long-term proliferation but inhibits iMSC differentiation, and that when OCT4 expression drops to baseline levels, iMSCs can initiate differentiation and eventually undergo senescence.
(B) Connective tissues derived from the implanted iMSCs (400×). Connective tissue was formed in all the implants (n = 10). (C) Adipose tissue derived from implanted iMSCs (400×). Adipose tissue was formed in all the implants (n = 10). (D) Muscle fibers differentiated from the implanted iMSCs (400×). Muscle fibers were found in most of the implants (n = 10). (E) The expression of GFP demonstrates that cells are differentiated from human GFP-transduced EV iMSCs (400×
The use of OCT4 for iMSC generation is likely a safe approach due to several reasons. First, OCT4 expression is detected in germline tumors, but rarely identified in somatic tumors [40] [41] . Second, although the inducible expression of OCT4 induces dysplasia in epithelial tissues, withdrawal of the induction stimulus leads to a complete reversal of the tumor-like phenotype. In addition, no mesenchymal tumor was observed in the OCT4 transgenic mouse model [27] . Third, iMSCs cultured in iPSC conditions do not form iPSC colonies, thus it is unlikely that iMSCs will induce teratoma formation after transplantation. In support of this notion, injection of Lenti iMSCs that express a high level of OCT4 does not induce tumors in immunodeficient mice. In contrast, coexpression of MYC in iMSCs did induce tumor formation (data not shown). Fourth, OCT4-generated iMSCs manifest a normal karyotype even after long-term culture, suggesting that ectopic OCT4 expression does not induce genomic abnormalities. In comparison, when MYC together with OCT4 was used for iMSC generation, chromosomal aneuploidies were observed (data not shown). Fifth, decreasing OCT4 expression to 5%-10% of the level expressed in iPSCs does not affect long-term self-renewal and expansion of iMSCs. A low level of OCT4 expression is sufficient to maintain iMSC self-renewal, but does not affect its multilineage differentiation, thus is unlikely to pose any significant risk in clinical use.
We provide compelling evidence that MSCs can be directly reprogrammed from hematopoietic cells. Although vascular and other endothelial cells also express CD34, the source cells we used for reprogramming also express CD45 (Supplementary information, Figure S2A and data not shown), arguing against the possibility that iMSCs are derived from endothelial cells. The timelapse video also demonstrates the morphological changes from hematopoietic cells to fibroblast-like cells (Supplementary information, Video S2). In addition, single-cell cloning experiment rules out the possibility that OCT4 overexpression expands contaminated MSCs in CD34 + cells (Supplementary information, Figure S4 ). Due to the unprecedented high reprogramming efficiency of 16%, our findings cannot be explained by the proliferation of trace amount of endothelial cells, MSCs or other types of unknown cells that express CD34.
Many in vitro studies used integrating-viral vectors for direct cell reprogramming. Although silencing of the viral vector was observed in some studies [14] , reactivation of the reprogramming factor may still pose a long-term risk after cell transplantation. Here, we show that OCT4 expression via a nonintegrating episomal vector is sufficient to induce direct reprogramming of CD34 + cells into iMSCS, making this approach one step closer to clinical therapy.
The capacity for long-term undifferentiated proliferation of iMSCs in the presence of low levels of OCT4 expression has important implications for MSC-based therapy. A low level of OCT4 expression in iMSCs does not affect iMSC terminal differentiation. This provides the possibility of a safe autologous MSC-based therapy, as one could select a clone with lentiviral vector integration at the "genomic safe harbors" for expansion and therapy. In this study, we used a weak promoter (Sca1) to drive the low-level OCT4 expression in EV iMSCs. Alternatively, identification of small molecules or microRNAs that can turn on OCT4 expression in MSCs may be useful for promoting the self-renewal of iMSCs and even adult MSCs.
Our study represents the first report that somatic stem cells can be efficiently reprogrammed from hematopoietic cells in adult human peripheral blood. Direct conversion of fibroblasts into cells of clinical interests has been reported by many groups. Due to the obvious advantages of using blood cells compared with fibroblasts derived from skin biopsy, our findings provide a foundation for further investigations into the possibility of direct conversion of blood cells into other cell types such as neural stem cells [14] , cardiomyocytes [16] [17] and hepatocytes [18] [19] . Alternatively, due to the biological similarities between fibroblasts and MSCs [42] [43] , iMSCs may also constitute a cell source comparable to fibroblasts for generating cells of clinical interest.
Materials and Methods
CB and PB CD34 + cells
The use of human CB was approved by the Institutional Review Board of Loma Linda University and written informed consent was obtained from all participants. CD34 + cells were purified with a CD34 Microbead Kit (Miltenyi Biotec, Auburn, CA, USA). Mobilized PB CD34 + cells were purchased from AllCells LLC (Emeryville, CA, USA). In conducting work involving the use of recombinant DNA, the investigators adhered to the current version of the National Institute of Health (NIH) Guidelines for Research Involving Recombinant DNA Molecules. The lentiviral vectors used in this study have been described previously [25] . In these vectors, the SFFV, EF1, PGK or Sca1 promoters were used to drive OCT4 expression at different levels in CD34 + cells [25] . The details of lentiviral vector packaging and titering have been published elsewhere [44] . In brief, the calcium precipitation method was used for generating lentiviral vector. After 100-fold concentration by ultracentrifugation, the biological titers of vectors were determined by transducing HT1080 cells. For generating integration-free iMSCs, OCT4 was subcloned into our improved ENBA/oriP-based episomal vector, in which the SFFV promoter and Wpre element were included to drive high-level transgene expression in hematopoietic cells [25] . For OCT4-KD, the shOCT4 lentiviral vector (catalog no: RHS3979-9573664) was purchased from Thermo Scientific Open Biosystems.
Lentiviral vectors and episomal vector
BM-MSCs
Human BM samples were purchased from AllCells, LLC. To generate BM-MSCs, whole BM was cultured in human fibronectin (BD Biosciences, San Jose, CA, USA)-precoated culture plates with the Mesenchymal Stem Cell (MSC) Medium Kit from Applied Biological Materials Inc. (ABM; Richmond, BC, Canada). The cultures were kept at 37 °C with 5% CO 2 in a water-jacketed incubator. Cells were cultured under hypoxia by placing culture plates in Hypoxia Chambers (Stemcell Technologies, Inc., Vancouver, BC, Canada) that were flushed with mixed air composed of 92% N 2 /3% O 2 /5% CO 2 . Culture medium was changed every 1-2 days. Approximately 10 days later, when MSC-like colonies appeared, cells were passaged every 3-5 days after treatment with accutase (Innovative Cell Technologies, Inc., San Diego, CA, USA) for 5 min. BM-MSCs at passages 3-6 were used in this study as a positive control. Some BM-MSCs were purchased from ABM.
iMSC generation with lentiviral or episomal vectors
To generate Lenti iMSCs, thawed human CB-CD34 + cells or G-CSF-mobilized PB-CD34 + cells (AllCells) were cultured in HSC culture medium: Iscove's modified Dulbecco's medium (IMDM; Life Technologies, Grand Island, NY, USA)/10% fetal bovine serum (FBS; ABM) supplemented with TPO, SCF and Flt3 ligand (FL) each at 100 ng/ml, and G-CSF and IL-3 at 10 ng/ml [45] . Cytokines were purchased from ProSpec (East Brunswick, NJ, USA). CD34 + cells were cultured for 2 days before transduction. For transduction, cells were inoculated in fibronectin fragment CH-296 (RetroNectin; Takara Bio Inc., Shiga, Japan)-pretreated non-TCwell plates and transduced with Lenti SFFV-OCT4 at a multiplicity of infection (MOI) of 2-5 for 4-5 h. A second transduction was performed the next day. To determine transduction efficiency, one well of cells were transduced with Lenti SFFV-GFP. After 2 transductions, 80%-95% cells were GFP + . OCT4-transduced cells were cultured in MSC medium. 4 to 6 days later, when CD34 + cells were morphologically transforming into MSC-like colonies, cells were split at a ratio of 4-6:1 to human fibronectin-treated non-TC plates. In some cultures, GSK3 inhibitor CHIR99021 (ABM) was also added at a final concentration of 3 µM. For long-term culture, cells were passaged every 2-3 days and cultures were maintained in hypoxia.
To generate integration-free iMSCs, fresh or thawed 1 × 10 6 CB-CD34 + cells were cultured in IMDM/10% FBS supplemented with TPO, SCF and FL at 100 ng/ml. 1 to 2 days later, cells were harvested for nucleofection with a total of 10 µg EV SFFV-OCT4 plasmid DNA. Human CD34 Cell Nucleofector ® Kit (Lonza, Koln, Germany) was used. Nucleofection was performed with Amaxa Nucleofector II using program U-008. Immediately after nucleofection, cells were suspended in HSC medium and gently transferred to a CH-296-pretreated non-TC well plate and spun down for 5 min at 400× g to improve cell survival. Starting the next day, MSC medium was added to the culture wells. At 1-2 weeks after nucleofection, when MSC-like colonies were formed, cells were passaged to human fibronectin-treated non-TC 6-well plates. In the first 2 weeks of culture, CHIR99021 (ABM) was also added at a final concentration of 3 µM. For long-term culture, episomal iMSCs were passaged every 2-4 days and cultures were maintained in hypoxia.
Single CD34 + cell cloning and iMSC generation
To rule out the possibility that some MSCs are carried along during CD34 cell enrichment, we conducted single cell cloning. Single CB-CD34 + cells were cultured in four U-bottomed 96-well plates in IMDM/10% FBS supplemented with TPO, SCF and FL at 100 ng/ml, and IL-3 and G-CSF at 10 ng/ml. Ten days later, colonies with more than 100 cells were formed in ~10% wells. Twelve clones were randomly selected and transferred to a CH-296-pretreated non-TC 12-well plate. After overnight transduction with Lenti SFFV-OCT4, cells were cultured in a mixture of HSC medium and MSC medium at a 20:80 ratio. At 5 and 8 days after transduction, cultures were refreshed with MSC medium. CHIR99021 (ABM) was added throughout the culture. At 10 days after transduction, the culture plate was stained with crystal violet stain.
Calculation of reprogramming efficiency
To calculate transdifferentiation efficiency, 1000 Lenti SFFV-OCT4-transduced CD34 + cells were seeded into CH-296-pretreated non-TC 6-well plates. HSC medium and MSC medium were added at a 20:80 ratio. In some wells, 3 µM CHIR99021 (ABM) was added to the medium. Five days later and every 2 days thereafter, the culture was refreshed with MSC medium. At 9 days after transdifferentiation of culture, the plate was stained with crystal violet stain and colonies were enumerated.
Cell imaging
Phase contrast pictures were taken using a Nikon converted microscope with a 10× objective. For time-lapse live cell imaging, CD34 + cells were transduced with Lenti SFFV-OCT4 or GFP control vectors. One day after transduction, 1 × 10 4 cells were seeded in each well of a CH-296-pretreated non-TC 6-well plate. Cells were cultured in HSC medium or MSC medium supplemented with 3 µM CHIR99021. At day 4, culture medium was changed. Phase contrast pictures of cells in culture were taken every 2 h for 6 days in a BioStation CT (Nikon Instruments Inc.) at UCR (University of California Riverside) Stem Cell Center Core Facility. The pictures were edited and videos composed with ImageJ.
Flow cytometry
To phenotype iMSCs, cells were stained with hematopoietic markers CD14, CD34 and CD45, endothelial marker CD31, MSC markers CD29, CD44, CD73, CD90, CD105 and CD166, and iPSC markers OCT4, SOX2, NANOG and TRA-1-60. All antibodies except otherwise specified were purchased from eBioscience, Inc. (San Diego, CA, USA). For staining of cell surface markers, CD14-FITC, CD29-APC (BD Biosciences), CD31-PE, CD34-PE, CD44-PE, CD45-FITC, CD73-APC, CD90-PE, CD105-APC, TRA-1-60-PE, CD166-PE (BioLegend, Inc., San Diego, CA, USA) cells were incubated with each antibody for 30 min at room temperature in FACS buffer in the dark. For intracellular staining, cells were fixed for 20 min at room temperature in a fixation buffer supplemented with 10% permeabilization buffer (eBioscience). After 2 washes with FACS buffer, cells were incubated with OCT4-PE, SOX2-FITC or NANOG-PE (BD Biosciences) for 2 h at room temperature in the dark. Following incubation, the samples were washed twice with FACS buffer supplemented with 10% permeabilization buffer. Flow cytometric analysis was performed using the FACS Aria II with a 488 nm laser (BD Biosciences).
In vitro differentiation of MSCs
For adipocytic differentiation, 1 × 10 5 iMSCs or BM-MSCs were seeded in each well of TC-treated 6-well plates. Adipocytic differentiation was induced with 1 µM dexamethasone (SigmaAldrich Corp, St Louis, MO, USA), 1 µM troglitazone (Sigma), 10 µg/ml insulin (Sigma), 0.5 mM isobutylxanthine (Sigma), 5 ng/ml of FGF2 (ABM) and 10% FBS in α-MEM (Life Technologies) with 1% penicillin/streptomycin (P/S). For osteoblastic differentiation, 2 × 10 5 cells were seeded in each well of TC-treated 6-well plates. Osteoblastic differentiation was induced with 0.1 µM dexamethasone (Sigma), 200 µM ascorbic acid (Sigma), 10 mM β-glycerol phosphate (Sigma), 10 ng/ml BMP2 (ABM), 10 ng/ml BMP4 (ABM) and 10% FBS in α-MEM. For chondrogenic differentiation, 4 × 10 5 cells were seeded in each well of TC-treated 6-well plates. Chondrogenic differentiation was induced in α-MEM/10% FBS/1% P/S supplemented with 0.1 µM dexamethasone, 200 µM ascorbic acid, 5.33 µg/ml linoleic acid, 0.35 mM L-proline, 10 ng/ml TGFβ3 (Stemgent, San Diego, CA, USA), 10 ng/ml TGFβ1 (ABM) and 1% ITS (insulin-transferrin-selenium; Life Technologies).
All cultures were maintained with 5% CO 2 in a water-jacketed incubator at 37 °C, and culture media were changed every 2-3 days. Three to four weeks after differentiation culture, cells were fixed in 10% neutral buffered formalin for 15 min before staining. Adipocytes were stained with Oil Red O solution for 15 min. Oil Red O working solution was made by diluting Oil Red O stock solution with nanopure water at a 3:2 ratio. Oil Red O stock solution was made by dissolving 0.5 g of Oil Red O powder in 100 ml isopropanol with gentle heat and then filtered with a 5 µm syringe filter. After 15 min of incubation with 1 ml of Oil Red O working solution, the stain was washed out with 60% isopropanol. Bone nodule formation was evaluated by Alizarin Red staining. After formalin fixation, 1 ml of Alizarin Red staining solution was added for 5 min and the cells were washed with nanopure water. Alizarin Red staining solution was made by dissolving 2 g of Alizarin Red in 100 ml of nanopure water. The pH was adjusted to 4.3 with 10% ammonium hydroxide and then filtered with a 5 µm syringe filter. To stain mucopolysaccharides associated with chondrocytic differentiation, fixed cultures were stained with Alcian Blue staining solution for 30 min. The cultures were later washed in tap water for 2 min and then rinsed in nanopure water. Alcian Blue staining solution was prepared by dissolving 1 g of Alcian Blue in 100 ml of 3% acetic acid solution. The pH was adjusted to 2.5 using acetic acid.
